Multibagger Selection: GPT-6's picks
GPT-6 picked INOD, ACMR, ADMA, AMSC, TMDX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 76% | — | — |
| 2 | ACMR | — | 73% | — | — |
| 3 | ADMA | — | 70% | — | — |
| 4 | AMSC | — | 66% | — | — |
| 5 | TMDX | — | 68% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -6.05% | -5.43% | 1.17x | 0 |
The model's market view
These five candidates combine identifiable operating milestones with sufficient trading liquidity and valuations that permit substantial upside under demanding assumptions. None is predicted to triple. Rankings emphasize 12-month potential and survivability rather than the next week's performance. Reverse valuations use the verified, rounded current equity capitalizations reported below. Scenario financials are hypothetical annual operating levels or forward annual estimates that investors would need to underwrite by October 23, 2027; they are not company guidance or consensus forecasts. They assume approximately constant share counts: dilution would require additional equity value to produce the same per-share return. Dollar-volume figures are calculated averages of daily Close multiplied by share volume across the 20 completed US Eastern sessions September 25–October 22, 2026. Quotes are asynchronous observations obtained while researching; later reference quotes do not change the authoritative prediction_time.
Why each pick
INOD
Innodata has the strongest demonstrated combination of growth, improving margins and cash generation in this shortlist. Reusable datasets and reinforcement-learning services offer a route to greater operating leverage than conventional labor-intensive annotation. The thesis requires expansion of existing programs, continued customer diversification and higher recurring earnings. Prospective wins that management has not finalized are not treated as contracted revenue. Screen 3 is supported through the documented customer-program ramp alternative; the complete historical-CAGR and two-year consensus test is data unconfirmed. Screen 7 is not claimed: institutional accumulation and improving relative strength were not established. Latest verified quote: $59.96 at 2026-10-23T11:42-04:00, regular session, labeled real-time by Stock Analysis.
ACMR
ACM Research combines expanding semiconductor-equipment categories with unusually large disclosed backlog relative to current revenue. The central opportunity is conversion of existing orders and successful qualification of additional process platforms. Screen 3 uses the documented product and order expansion alternative. Screen 7 is supported by Daiwa initiating coverage in September, not by an inferred institutional-accumulation claim. Screen 4 is excluded because gross margin declined year over year. Screen 5 is excluded because a positive FCF inflection within 12 months is not established, despite substantial consolidated liquidity. Latest verified quote: $50.94 at 2026-10-23T11:43:54-04:00, regular session; Google Finance's extracted page did not establish its delay classification.
ADMA
ADMA offers a different route to extreme upside: a profitable specialty-biologics business whose product mix has improved much faster than total revenue. The scenario depends on ASCENIV growth overcoming BIVIGAM weakness while preserving manufacturing economics. It is retained for earnings and cash-flow support rather than headline growth. Screen 3 is not claimed because total-company revenue growth remains weak; screen 7 is unconfirmed. Latest verified quote: $10.62 at 2026-10-23T11:40-04:00, regular session, labeled real-time by Stock Analysis.
AMSC
American Superconductor has a comparatively small equity base, an established power-equipment business and booked demand that can support growth without depending on an unannounced breakthrough order. The opportunity is backlog conversion combined with better acquired-business economics. Screen 3 uses documented backlog and expansion rather than an unverified consensus-growth test. Screen 4 is excluded because current gross margin is below 30% and deteriorated; management's improvement expectation is not yet proof of material expansion. Screen 7 is unconfirmed. Latest verified quote: $25.16 at 2026-10-23T11:26-04:00, regular session, labeled real-time by Stock Analysis.
TMDX
TransMedics offers an established organ-preservation and logistics platform with positive cash generation and several identifiable expansion milestones. The upside case is renewed clinical adoption and operating leverage after an investment-heavy period. Screen 3 uses documented commercialization and geographic expansion. Screens 2 and 4 are excluded because current earnings conversion and year-over-year gross margin weakened. Screen 7 is supported by Barclays initiating coverage in October, rather than inferred institutional buying. Latest verified quote: $72.28 at 2026-10-23T11:41-04:00, regular session, labeled real-time by Stock Analysis.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | BKSY, LPTH, INOD, LMND, OUST |
| Gemini 3 Pro | RKLB, SOUN, LUNR, RXRX, ACHR |
| Grok 4.7 | NTLA, VKTX, ONDS, LUNR, MGTX |
| Muse Spark 1.1 | BHVN, EOSE, CAPR, SERV, MSM |
| DeepSeek | UMAC, INOD, KRMN, SEZL, BCRX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.